Regeneron has been on an amazing run. The company seemingly can't raise guidance of its new drug Eylea fast enough. After a blowout quarter and another revision that caused shares to pop, investors should start to wonder whether the company is priced for perfection, as well as whether any little stumble could trigger a massive sell-off. Watch and hear what senior health-care analyst David Williamson thinks of Regeneron and its prospects.
Biotechs like Regeneron are constantly disrupting the status quo in health care, but there are other revolutions growth investors need to pay attention to. The Motley Fool has compiled a new report called "The Only Stock You Need to Profit From the NEW Technology Revolution." The report highlights a company that has gained 300% since first recommended by Fool analysts but still has plenty of room left to run. Thousands have requested access to this special free report, and now you can access it today at no cost. To get instant access to the names of this company transforming the IT industry, click here -- it's free.